NasdaqCM - Nasdaq Real Time Price USD
BioVie Inc. (BIVI)
At close: 4:00 PM EDT
After hours: 4:34 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | -11.8 | -5.8 |
| Low Estimate | 0 | 0 | -11.8 | -5.8 |
| High Estimate | 0 | 0 | -11.8 | -5.8 |
| Year Ago EPS | -4.3 | -2.5 | -15.5 | -11.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.55 | -3.99 | -3.1 | -3.17 |
| EPS Actual | -4.3 | -2.5 | -2.9 | -2.2 |
| Difference | -0.75 | 1.49 | 0.2 | 0.97 |
| Surprise % | -21.10% | 37.30% | 6.50% | 30.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -11.8 | -5.8 |
| 7 Days Ago | -0.33 | -0.15 | -11.8 | -5.8 |
| 30 Days Ago | -0.33 | -0.15 | -11.8 | -5.8 |
| 60 Days Ago | -0.33 | -0.15 | -11.8 | -5.8 |
| 90 Days Ago | -0.33 | -0.15 | -1.18 | -0.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BIVI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 4.40% |
| Next Qtr. | -- | -- | -- | 7.80% |
| Current Year | 23.90% | -- | -- | 2.50% |
| Next Year | 50.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Initiated | ThinkEquity: Buy | 7/1/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/30/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/22/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 7/18/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/17/2023 |
| Reiterates | Oppenheimer: Outperform to Outperform | 5/17/2023 |
Related Tickers
STTK Shattuck Labs, Inc.
1.4500
-2.68%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.2300
0.00%
GLYC GlycoMimetics, Inc.
0.1569
+2.95%
BCDA BioCardia, Inc.
2.6350
+7.99%
AZTR Azitra, Inc.
0.5468
+5.15%
CGTX Cognition Therapeutics, Inc.
0.4478
+4.65%
PALI Palisade Bio, Inc.
3.6900
+4.83%
CADL Candel Therapeutics, Inc.
6.23
+4.62%
NKGN NKGen Biotech, Inc.
0.2755
+19.78%
ANVS Annovis Bio, Inc.
9.14
+14.54%